Exosomes vs PDRN: Choosing the Right Regenerative Injectable for Your Patient
Two of the most clinically significant injectable categories in modern aesthetic medicine — polynucleotides/PDRN and exosomes — are frequently compared by practitioners trying to determine which to offer, which to prioritise for specific patients, and whether there is clinical value in using both. The comparison is worth making carefully, because the two treatments operate through genuinely different mechanisms, have different evidence bases, suit different patient profiles in some respects, and produce their best outcomes in different clinical contexts.
Korean Exosome Products: A Practitioner's Guide to Selection and Use
The aesthetic exosome market is growing rapidly and unevenly. Alongside genuinely well-characterised, rigorously manufactured Korean products with transparent documentation, the market contains preparations making compelling regenerative claims while providing minimal evidence of their actual content, source, or regulatory classification. For practitioners, the ability to evaluate exosome products on scientific and regulatory grounds is essential.
Korean PDRN Products: A Practitioner's Guide to Selection and Use
South Korea is the world's leading producer of pharmaceutical-grade PDRN injectables. The Korean PDRN industry has been developing, manufacturing, and exporting these products for over two decades — a timeline that gives Korean manufacturers an accumulated clinical knowledge base and manufacturing expertise that no other country's PDRN industry can currently match. For UK and EU practitioners, this means the best available PDRN products are, almost without exception, Korean in origin.
Polynucleotides and PDRN: The Complete Practitioner's Guide
Polynucleotides — sold under a variety of brand names and delivered through a growing range of injection products — have become one of the most talked-about categories in UK aesthetic medicine. They are also one of the most misunderstood. Practitioners encounter them under different terminology (PDRN, PN, polynucleotide, polydeoxyribonucleotide), from multiple manufacturers, with variable claimed mechanisms, and with an evidence base that ranges from well-established to preliminary depending on the specific application and product.
